Skip to Content
  • Invisible Crystals Yield Structure

    A crystallographer colleague passes on this new paper, which I find very interesting and just a bit freaky. The authors (a collaboration between UCLA, HHMI, LBN… Read More
  • Target Invalidation

    Target validation is a key process in drug discovery, naturally. But it’s worth remembering that target invalidation happens more often, and is also impor… Read More
  • Bromodomain Ligands and Memory

    Epigenetics has been a hot field the last few years (although not quite hot enough for Roche to buy out their partners in the area, Constellation). One of the t… Read More
  • A 3D Printed Drug?

    Several readers have sent along news of what’s billed as the “world’s first 3D-printed drug”. That got my attention, because there have… Read More
  • Sertraline in the Courts

    Potential trouble: thoughts of a link between cardiac birth defects and the antidepressant Zoloft (sertraline). Pfizer recently won such a case in Missouri, but… Read More
  • Four Patients. Count ‘Em, Four.

    While we’re on the subject of market froth, take a look at what’s going on today. Sage Therapeutics announced the results of a study in post-partum… Read More
  • Some Side Effect For An Antibody

    Remember back when AstraZeneca was fighting off Pfizer’s ardent, tax-issue-resolving embrace a year ago? One of their weapons was a pitch to their own sha… Read More
  • More on TC-2153

    Yesterday’s post on TC-2153 and its assay activity brought a note from Paul Lombroso at Yale, whose group is doing this work. With his permission, here… Read More
  • Sulfur, Sulfur, Sulfur

    Does anyone know of any phosphatase inhibitors that aren’t hideous? I ask this because someone sent along a question about this paper, from last August, t… Read More
Page 4 of 17« First...23456...10...Last »